Fig. 6

Inflammation and astrogliosis at 7 days after treatment. a Inflammatory markers (COX-2, IL-6, TNF-α). COX-2 levels were decreased in all treatment groups. The levels of IL-6 and TNFα were decreased in AD-MSCs and AD-MSCs + MPSS groups. b Astrogliosis and neuronal markers (pSTAT3, β3-tubulin, GFAP, GalC). Expression of pSTAT3 was decreased in the AD-MSCs and AD-MSCs + MPSS groups. β3-tubulin levels were increased in all treatment groups. Data presented as mean ± SD. *P <0.05 compared with the control group. AD-MSCs adipose-derived mesenchymal stem cells, COX cyclooxygenase, GalC galactosylceramidase, GFAP glial fibrillary acidic protein, IL interleukin, MPSS methylprednisolone sodium succinate, pSTAT3 phosphorylated signal transducer and activator of transcription 3, TNFα tumor necrosis factor alpha